The value proposition does not define the leadership of the partnership. The proper answer is A. This proposition signifies a commitment to generate value. Achieving this involves the collaboration of multiple individuals and strategies to fulfill that promise. Shared objectives, changes, and the involvement of partners are critical components of the value proposition.
The raw materials price variance amounts to $14,016 favorable.
The calculation for this variance is done as follows:
= Actual Quantity × (Standard Price - Actual Price)
= 23,360 liters × ($5.40 - $4.80)
= 23,360 liters × $0.6
= $14,016 favorable
This is derived by taking the standard price, subtracting the actual price, and multiplying the difference by the actual quantity to arrive at the finalized value.
Part a. Produce the goods in-house and allow international sales managers to oversee marketing.
Advantages include:
- Complete authority over production processes.
- Simplicity in strategizing and scaling manufacturing.
- Enhanced control over human resources.
- Increased comprehension of European markets by foreign sales agents.
- Reduced exit costs in case of product failure.
Disadvantages consist of:
- Limited knowledge regarding pharmaceutical protocols in Europe.
- Risks to the brand's reputation if not correctly managed by foreign agents.
- Extra expenses in product delivery.
Part b. Produce the items in-house and establish a wholly-owned entity in Europe for marketing.
Pros encompass:
- Full oversight of manufacturing operations.
- Ease in creating strategies and ramping up production.
- Better human resource oversight.
- Protection of brand integrity since marketing is managed internally.
Cons include:
- Increased resource allocation for marketing.
- Insufficient information about pharmaceutical standards in Europe.
- Extra delivery costs.
Part c. Form a strategic partnership with a significant European pharmaceutical entity to manufacture products via a 50/50 joint venture for marketing.
Pros involve:
- Risk-sharing among the enterprises.
- No additional costs for delivery.
- Valuable insights into European regulations and marketing.
Cons involve:
- Diminished control over manufacturing.
- Share profits among partners.
- Moderate exit costs involved.
- Possible brand image damage due to the additional firm.
